Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer Article

publication date

  • April 28, 2023

webpage

published in

keywords

  • PSA progression
  • castration resistance
  • mCSPC
  • overall survival
  • radiographic progression-free survival

start page

  • 477

end page

  • 485

volume

  • 34

issue

  • 5